Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02341014 · ClinicalTrials.gov registry record · Phase 1
Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
A Phase 1 study of T-cell Lymphomas and Relapsed or Refractory, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 6
- Study locations
NCT02341014: Completed Phase 1 study of T-cell Lymphomas and Relapsed or Refractory, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02341014 is a Phase 1 study of T-cell Lymphomas and Relapsed or Refractory that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 27 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower). The trial reports 6 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02341014, a Phase 1 study of T-cell Lymphomas and Relapsed or Refractory, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is an open label phase Ib/IIa study of patients with relapsed/refractory B- and T-cell lymphomas who are treated with carfilzomib, lenalidomide and romidepsin.
Primary Outcome
Determine the MTD by NCI-CTCAE v4.0.
Conditions Studied
Interventions
- DRUG Lenalidomide
- DRUG Carfilzomib
- DRUG Romidepsin
Study Locations (6)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering at Mercy Medical Center - Rockville Centre
Nebraska
- University of Nebraska Medical Center - Omaha
New Jersey
- Memoral Sloan Kettering Cancer Center - Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2015-01-02 |
| Est. Completion | 2023-01-11 |
| Phase | Phase 1 |
What the finished NCT02341014 record still lists
NCT02341014 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower).
The record links to 2 conditions, with T-cell Lymphomas appearing as the primary indexed condition, and to 3 interventions - of which Lenalidomide is the first listed.
NCT02341014 lists 6 locations in 3 states (New York, Nebraska, New Jersey).
Frequently Asked Questions
What is clinical trial NCT02341014 about?
NCT02341014 is a clinical study titled "Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas". This is an open label phase Ib/IIa study of patients with relapsed/refractory B- and T-cell lymphomas who are treated with carfilzomib, lenalidomide and romidepsin.
What is the current status of trial NCT02341014?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2015-01-02. Estimated completion is 2023-01-11.
What conditions does trial NCT02341014 study?
This clinical trial studies the following conditions: T-cell Lymphomas, Relapsed or Refractory.
What interventions are being tested in trial NCT02341014?
The interventions under investigation include: Lenalidomide (DRUG), Carfilzomib (DRUG), Romidepsin (DRUG).
Who is sponsoring clinical trial NCT02341014?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02341014 being conducted?
This trial has 6 study locations across Nebraska, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for T-cell Lymphomas
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02341014's enrollment target sits among peer trials
27 1463rd of 2000 higher than 519 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI